Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medunik Canada, a pharmaceutical company, has concluded strategic collaboration agreement with QOL Medical, to acquire the exclusive Canadian rights to market Sucraid (sacrosidase) and Ethamolin (Ethanolamine Oleate), used in treatment of rare diseases.
Subscribe to our email newsletter
Sucraid oral solution is an enzyme replacement therapy (ERT) for genetically determined sucrase deficiency, which is part of a rare, chronic disease, congenital sucrase-isomaltase deficiency (CSID).
Ethamolin (Ethanolamine Oleate injection, 5%, 2mL ampules) is a mild sclerosing agent, used to treat patients with esophageal varices that have recently bled, to prevent rebleeding.
QOL Medical chief operating officer Derick Cooper said their company is seeking to jointly make life changing medications available to patients in Canada, along with Medunik Canada.
"Our company’s mission is to assist in expanding disease awareness to aid physicians with identifying these rare diseases and to assist, directly and with partners like Médunik Canada, in making the proper treatments available to physicians and patients," Cooper added.